Phase III Flop Narrows Odds On Targacept Antidepressant, But Three Trials Remain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.